{"id":"NCT00534833","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™","officialTitle":"Immunogenicity Study of the Antibody Persistence and Booster Effect of DTaP-Hep B-PRP-T Combined Vaccine or Tritanrix HepB/Hib™ at 15 to 18 Months of Age Following a Primary Series at 6, 10 and 14 Weeks of Age in Healthy Filipino Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-09","completion":"2009-03","firstPosted":"2007-09-26","resultsPosted":"2013-11-21","lastUpdate":"2013-11-21"},"enrollment":362,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Haemophilus Influenzae Type b"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-HB-PRP~T vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Tritanrix-HepB/Hib™","otherNames":[]},{"type":"BIOLOGICAL","name":"Oral Polio Vaccine","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"}],"summary":"The present trial is a follow-up of AL203 study (NCT00343889).\n\nPrimary Objectives:\n\nTo describe the antibody persistence at 15 to 18 months of age and the booster effect of a dose of DTaP-HB-PRP\\~T or Tritanrix-HepB/Hib™ (given concomitantly with Oral Polio Vaccine \\[OPV\\]).\n\nSecondary Objective:\n\nTo describe the safety profile of a booster dose of DTaP-HB-PRP\\~T or Tritanrix-HepB/Hib™ when administered concomitantly with OPV in each vaccine group.","primaryOutcome":{"measure":"Summary of Antibody Persistence and Immunogenicity Booster Response in Participants Who Were Vaccinated With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","timeFrame":"28 Days post-vaccination","effectByArm":[{"arm":"Group 1: DTaP-Hep B-PRP~T + OPV","deltaMin":36,"sd":null},{"arm":"Group 2: Tritanrix-Hep B/ Hib™ + OPV","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":2,"countries":["Philippines"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":182},"commonTop":["Injection site pain","Injection site erythemia","Irritability","Upper respiratory tract infection","Pyrexia"]}}